Compare AbbVie Inc (ABBV) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Robinhood Markets, Inc. — how do they compare? AbbVie Inc trades at $253.71 (market cap $449.91B), while Robinhood Markets, Inc. trades at $112.61 (market cap $101.67B). The key difference: AbbVie Inc is far larger — about 4.4× Robinhood Markets, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | HOOD | |
|---|---|---|
Market Cap | $449.91B | $101.67B |
Sector | Health | Technology |
52-Week High | $261.07 | $152.46 |
52-Week Low | $184.85 | $65.16 |
Enterprise Value | $513.38B | $102.87B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Robinhood (HOOD) trades at $112.90, up 0.15% with strong technical momentum as it approaches resistance near $116. The stock shows robust fundamentals with 2025 revenue reaching $4.47 billion and net income of $1.88 billion, though valuation metrics remain elevated with a P/E of 57.06. Recent positive sentiment stems from international expansion and new product launches, including AI-powered trading tools and the Trump Accounts program announced July 2026.
Outlook remains positive with 73% analyst buy ratings and $108.13 consensus target, though the stock trades above target. Key opportunities include continued revenue growth and banking expansion, while risks involve high valuation multiples and cryptocurrency revenue volatility. Q2 2026 earnings on July 29 will be crucial for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
